The recent approval of Sipuleucel-T (Dendreon, Seattle, WA) from the Food and Drug Administration for the treatment of men with asymptomatic or minimally symptomatic castrate-resistant prostate cancer was a landmark in cancer immunotherapy, making this the first cancer ''vaccine'' approved for use in a treatment setting. This approval has led to renewed interest in cancer vaccines and to the recognition that prostate cancer represents an immunologically sensitive disease. At the current time, several vaccine approaches are under clinical investigation. These include viral vectors, antigen-loaded dendritic cells, and DNA vaccines. Each approach has its own set of advantages and disadvantages. This review will introduce the basic technology underlying these different vaccines and briefly discuss completed and ongoing clinical trials. As a great number of prostate cancer vaccines have been investigated in both preclinical and clinical settings, we will focus primarily on vaccines that are currently in clinical trials, as ascertained by a recent inquiry of the clinical trials database, www.clinicaltrials.gov.
P rostate cancer is the most commonly diagnosed nonmelanoma malignancy in the United States, with a lifetime incidence of approximately 1 in 6. 1 Initial (primary) therapy involves surgery, radiation therapy, or hormonal therapyValthough recent studies suggest that carefully selected men with low-grade disease may be carefully observed over time. 2 About one third of patients treated with primary therapy eventually develop recurrent disease, usually presenting as a rise in the serum level of prostate-specific antigen (PSA). Recurrent disease is slowly progressive, with a median time from PSA rise to detectable metastases of approximately 7 years, 3 and a median survival more than 10 years. This protracted disease course may permit sufficient time for an immune response to develop after vaccination and may also enable the repetitive vaccination schedules that might be required for an optimal anti-tumor immune response (Table 1) .
DENDRITIC CELLYBASED VACCINES

Sipuleucel-T Description
In 2010, the US Food and Drug Administration (FDA) approved Sipuleucel-T (Dendreon, Seattle, WA) for the treatment of men with either asymptomatic or minimally symp-tomatic metastatic, castrate-resistant prostate cancer (mCRPC). This approval, based on a blinded, randomized controlled trial, represented the first vaccine approved to treat established cancer of any type. 4 Development of this platform, however, began almost 15 years earlier, with the demonstration that immunization of male rats with rat or human prostatic acid phosphatase (PAP) in complete Freund's adjuvant resulted in autoimmune, lymphocyte-mediated prostatitis. 5 These findings were important, demonstrating that tolerance to this particular prostaterestricted protein was not centrally mediated and that vaccination could induce an immune response against a so-called self protein from the prostate gland. To translate this approach to the clinic, a modified dendritic cell (DC) vaccine platform was developed.
Here, a patient's peripheral blood leukocytes are harvested via leukapheresis, and then monocytes are enriched via buoyant density centrifugation. To generate the vaccine product, these enriched monocytes are incubated for approximately 36 hours with a unique fusion protein, which couples the target antigen (PAP) to the cytokine granulocyte macrophage colony stimulating factor (GM-CSF). In this platform, GM-CSF most likely serves to traffic the target antigen to receptors on DC precursors, which then present peptides from PAP on their cell surface in a context sufficient to activate specific CD4 and CD8 T cells. Activated, PAP-presenting DC thus serves as the ''vaccine,'' and the goal is the generation of a specific anti-PAP immune response. It should be noted, however, that the final product infused into patients contains other cell types as well and that the inclusion of these additional cell types may be important in the potency of this product. Potential advantages of this approach include the ex vivo DC maturation step; multiple studies show that DC within cancer patients are deficient in both number and function. 6 In addition, the vaccine is administered 3 times at 2-week intervals, leading to increased immune activation of the infused product over time. The major disadvantage of Sipuleucel-T is the complexity involved in its manufacture, involving shipping the leukapheresis product to a central processing facility, ex vivo culture, and then shipping the finished product back to the treatment center for infusion.
Clinical Development/Ongoing Trials
Two phase I trials showed that vaccination with PAP-loaded DC was generally well tolerated and that T-cell responses to PAP could be detected after vaccination. 7, 8 In one of these trials, 7 several patients demonstrated a greater than 50% drop in serum PSA levels, suggesting clinical activity. A small randomized phase III trial confirmed that finding. 9 In that study (D9901), 127 patients with mCRPC were randomized 2:1 to active vaccination with Sipuleucel-T or to placebo. The primary end point of this study, progression-free survival, was not met, but a planned secondary end point, median overall survival, showed a significant improvement in the treatment arm (25.9 vs 21.4 months; hazard ratio = 1.70, P = 0.01). These data were eventually confirmed in a pivotal phase III trial (D9902B). Here, 512 men with asymptomatic or minimally symptomatic mCRPC were once again randomized 2:1 to receive active vaccination versus placebo. Patients who subsequently progressed on the placebo arm were given the opportunity to participate in a salvage protocol in which active vaccine was manufactured from crypopreserved peripheral blood lymphocytesVa crossover to active treatment was possible. The primary end point of this trial, overall survival, was met with a survival of 25.8 months in the Sipuleucel-T group versus 21.7 months in the men initially treated with placebo (hazard ratio = 0.77, P = 0.02). Although both clinically and statistically significant, these results were not without controversy because the trial design could potentially lead to a slight delay in chemotherapy treatment in the control group. In addition, a secondary time to progression (TTP) end point was not met, raising interesting questions regarding the precise mechanism of action of this agent, that is, how can one observe an increase in overall survival without radiologic evidence of tumor response.
Multiple preclinical and clinical studies support the concept that tumor vaccines may function optimally in patients with a decreased tumor burden. 10 Thus, now that FDA approval has been secured, one obvious developmental pathway for Sipuleucel-T would be to explore efficacy in men with earlier stages of prostate cancer. In particular, men with biochemically recurrent but nonmetastatic prostate cancer are often treated with androgen ablation, an intervention with well-documented antitumor immunologic effects. 11Y14 Combining androgen ablation with prostate cancer vaccines would therefore seem a logical proposition. However, it is not clear whether the optimal therapeutic sequence is to vaccinate before or after androgen ablation. 15 A clinical trial exploring Sipuleucel-T in this context was recently announced. 16 Here, men with biochemically recurrent prostate cancer will receive either androgen ablation followed by Sipuleucel-T or the 2 agents in the opposite order. The primary end points of this randomized trial are immunologic, the eventual goal being an future interventional trial comparing the optimal combination regimen to androgen ablation alone.
TumorYMessenger RNA Transfected Dendritic Cells
Description
Because activated DCs are the most potent immune cell in initiating an adaptive immune response, 17 they represent an attractive platform on which to base cancer vaccines. 18 Ex vivo generation of such cells is relatively straightforward, involving the maturation of peripheral blood mononuclear cells in the presence of certain cytokines (usually interleukin 4 and GM-CSF). To make a cancer vaccine, DCs are loaded with antigen and are then matured to maximize antigen presentation to T cells and potentially B cells. The source of tumor antigen in these vaccines is important and may involve synthetic peptides, autologous tumor cell lysates, or lysates from cultured cancer cells. Using autologous tumor cell lysates is a particularly attractive option, as immunization is thus directed against the antigen repertoire derived from a patient's own individual tumor. However, autologous cells vary greatly in number, viability, and recovery and require a sufficient surgical sample for vaccine to be made. Some of these issues may be circumvented by using cancer cell lines cultured in vitro, but the expression profile of such allogeneic cells may or may not intersect with the antigens present in the patient's cancer. Some recent work in this area focuses on using tumor cellYderived messenger RNA (mRNA) to transfect cultured DCsVthis approach can be standardized by extracting sufficient quantities of mRNA from cultured tumor cells 19 and has shown preclinical evidence of efficacy in animal models. Overall, the advantages of this approach include the presentation of a broad spectrum of antigens, as well as a potential augmentation of the immune response conferred by the non-self major histocompatibility complex molecules present in 
Clinical Development/Ongoing Trials
A phase I trial using autologous (patient-derived) DCs transfected with mRNA from allogeneic prostate tumor cells was recently published. 20 Here, patients with mCRPC were treated with 4 doses of DCs transfected with mRNA from the prostate cancer cell lines LNCaP, DU145, and PC-3. The vaccine was well tolerated and resulted in a decrease in the rate of PSA progression in 13 of 19 treated patients. Immune responses (proliferation to transfected DCs) were documented and seemed to correlate with PSA responses, although patient numbers were small. This work has recently been extended clinically in the form of an active phase I/II trial using autologous tumor cells as an antigen source (NCT01197625).
VIRUS-BASED VACCINES
ProstVac VF
Description
Another method to generate an immune response against a particular target antigen is to couple that antigen to a viral backboneVin these approaches, the multiple viral proteins serve to initiate a potent immune response. The advantage of such approaches is their immunogenicity and the off-the-shelf nature of the ensuing construct, which does not need to be individually prepared for each patient. The major disadvantage of viral vaccine constructs is the complex nature of the viral backbone, which means that most of the immune response is targeted against the virus itself rather than the target antigen. This property makes repeated dosing particularly challenging, and the immune response to subsequent vaccinations may rapidly neutralize response to the target antigen. To circumvent these limitations, the National Cancer Institute group has added 2 significant innovations. 21 In the first, immunogenicity of the standard vaccinia vector was dramatically improved by the addition of 3 immunomodulatory proteins (LFA-1, ICAM, and B7-1). 22 Preclinical studies showed that this combination was strikingly synergistic in generating a targeted immune response, and this technology was adapted for clinical development. The second modification of a standard vaccinia approach was the observation that heterologous primeYboost regimens could be used, providing that a second viral backbone was used. In target antigen, this group chose PSA. This choice was based on several factors, including the notion that PSA is rather exclusively expressed by the prostate gland and by prostate cancer. Prostatespecific antigen may also play a functional role; several studies showed that increasing PSA levels confer increasing pathogenicity. 23 The major advantages of this methodology include the off-the-shelf nature of the vaccine vector as well as the well-optimized nature of the technology. The relative disadvantages of this platform include the univalent nature of the targeted protein (PSA), although some clinical studies have suggested that spread of the immune response to prostate cancer antigens not originally targeted by the vaccine may occur. 24 
Clinical Development/Ongoing Trials
As the clinical development of ProstVac VF has recently been reviewed, 25 only selected trials will be highlighted here. In early development, one important early trial of vacciniaYPSA was that performed to determine the optimal sequencing of a heterologous primeYboost regimen. This trial was critical; it showed that a vacciniaYPSA prime, followed by a series of fowlpox-PSA boosts, was more immunogenic than other regimens. 26 A carefully considered series of combination trials followed, involving chemotherapy, radiation therapy, and androgen ablation. Most recently, an important randomized phase II trial of ProstVac VF was reported. 27 This was a randomized phase II trial, similar in design to the pivotal trial of Sipuleucel-T. Men with asymptomatic or minimally symptomatic mCRPC were enrolled and randomized 2:1 to treatment with either ProstVac VF or placebo. The primary end point of this trial was TTP, and on progression, men were treated at their physicians' discretionVno crossover was permitted. Although the primary end point was not met, long-term follow-up showed a statistically significant improvement in overall survival for the treatment group (25.1 vs 16.6 months; hazard ratio = 0.56, P = 0.006). Because overall survival was a secondary end point in this study, those data must clearly be considered hypothesis generating rather than definitive. Nevertheless, the observed improvement in survival was sufficiently intriguing that the technology is now being commercially developed (Bavarian Nordic, Mountain View, CA), and a phase III registration trial is planned to open to accrual in late 2011 (NCT01322490). This international trial will randomize approximately 1200 men to ProstVac VF, to ProstVac VF with GM-CSF as an adjuvant, or to placebo. The primary end point of this study is overall survival. In keeping with previous results, 10 enrollment will be limited to men with favorable prognostic characteristics.
Another ongoing trial involving ProstVac VF tests the hypothesis that vaccination can improve the clinical efficacy of a subsequent treatment modality, in this case chemotherapy. This notion is well supported by preclinical data, 28 but certain chemotherapy regimens are clearly more immunogenic than others. In this Eastern Cooperative Oncology Group trial, men with slowly progressing mCRPC are randomized either to standard docetaxelbased immunotherapy or to a course of ProstVac VF (administered during 12 weeks) followed by standard chemotherapy. The primary end point of this study (NCT01145508) is overall survival, as suggested by the phase II data described previously. In addition, immune response and TTP will be evaluated as secondary end points. This is a significant trial in that it represents a formal attempt to evaluate the effect that cancer vaccination may have on subsequent therapy and, in that sense, is broadly applicable to other tumor types and vaccine approaches as well.
TroVax
Description
The TroVax vaccine platform was based on the identification of a cell surface glycoprotein (5T4) as a potential tumorspecific target is several cancer types, including colorectal, renal and prostate cancer. 29 A vaccine against 5T4 was engineered by incorporating 5T4 into a viral vector, in this case, modified vaccinia AnkaraVan alternative vaccine against smallpox generally used in immunocompromised hosts. Unlike the ProstVac VF vaccine described, TroVax does not include a heterologous primeYboost and does not include a series of costimulatory molecules. A phase III trial in patients with renal cell cancer did not result in improved survival compared with placebo, but subgroup analyses did suggest an improved survival in patients with a favorable prognosis. 30 Preclinical data suggest that this vaccine functions through a CD4 T-cell and antibody-mediated mechanism and that CD8 T cells are not required for efficacy, 31 rendering it somewhat unique from the other approaches discussed here. The primary advantage of this platform is the novel target antigen, which might be broadly applicable to multiple tumor types. The major disadvantages are the univalent nature of the vaccine construct, as well as a homologous primeYboost regimen.
Clinical Development/Ongoing Trials
An open-label phase II trial in men with mCRPC as recently reported. 32 Here, 27 men with progressive disease were treated, 13 with TroVax alone and 14 with a combination of TroVax and GM-CSF. The agent was generally well tolerated, with few adverse reactions reported. Five patients in the combined treatment group showed a PSA decline, whereas none were noted in the TroVax alone group. Currently, this agent is being evaluated in a randomized phase II trial similar to the Eastern Cooperative Oncology Group trial of ProstVac VF described, comparing vaccination plus chemotherapy to chemotherapy alone in men with mCRPC (NCT01194960).
Adenovirus/PSA
Adenoviral vaccines represent an additional vector suitable for targeting tumor antigens, and some preclinical data suggest that these vectors might be more immunogenic than vaccinia-or canarypox-based vaccines. 33 A major challenge to adenoviralbased vaccines is the presence of preexisting neutralizing antibodies resulting from prior environmental exposure, which can neutralize adenoviruses before a strong T-cell response is generated. Interestingly, the Ratliff group found that incorporation of an adenoviral vaccine targeting PSA (Ad/PSA) in a Gelfoam matrix (Pharmacia) permitted this vaccine to induce anti-PSA response even in the presence of high-titer antibodies. 34 The advantages of this platform include the relative immunogenicity of the adenoviral vector; a relative disadvantage might be the variation in preexisting antibody responses to adenoviruses in human patients.
Clinical Development/Ongoing Trials
A phase I trial of Ad/PSA with our without Gelfoam matrix was recently reported. 33 The agent was shown to be safe (the primary end point of the trial), and anti-PSA T-cell responses were documented in most treated patients. As is the case for several of the other vaccine trials described here, an increase in the rate of rise of PSA (PSA doubling time) was noted in approximately half of the patients treated. Interestingly, Gelfoam had a mixed immunologic effect and was associated with a decreased percentage of anti-PSA antibody responses, but increasing T-cell responses as well as PSA doubling times. On the basis of these data, 2 new phase II trials have been initiated and are currently recruiting. The first (NCT00583024) is a standard single-arm phase II trial with the primary end point of PSA doubling time versus that before enrollment. The second and perhaps more interesting trial will enroll men with biochemically recurrent disease and randomize them to either Ad/PSA vaccine or Ad/PSA vaccine plus androgen ablationVan intervention with multiple immunologic effects as described above.
DNA VACCINES Description
The concept that naked DNA, injected intramuscularly, could induce a meaningful immune response was first described several decades ago, 35 and DNA-based vaccines have been evaluated in several cancer types, including breast, colon, and prostate cancer. 36 Generating such vaccines is relatively straightforward, especially when compared with the DC and other vaccine platforms described. In general, the target antigen is simply engineered into a suitable expression plasmid. Largescale manufacture is similarly straightforward, involving standard bacterial culture and DNA isolation technologies. These characteristics form the basis for the primary advantage of DNA vaccines over competing technologies; the ability to rapidly target different antigens. The primary disadvantage of DNAbased vaccines is their relatively poor immunogenicity, especially compared with the relatively potent DC and viral-based approached described. This weakness has been partially addressed by the incorporation of additional stimulatory molecules (such as toll-like receptor agonists) into DNA vaccine backbones, but their relatively weak immunogenicity remains a major challenge to the development of DNA vaccines for prostate cancer. Preclinical data have recently been summarized 36 and are mostly remarkable for the wide variety of target antigens that have been evaluated, including PSA, prostate-specific membrane antigen, PAP, prostate stem cell antigen, and six transmembrane epithelial antigen of the prostate.
Clinical Development/Ongoing Trials
An important phase I trial of DNA vaccination in prostate cancer was recently reported. 37 Here, the target antigen was PAP, and patients with early stage (biochemically recurrent, nonmetastatic, disease) were enrolled. The DNA vaccine dose was escalated, and the vaccine was administered along with GM-CSF. Anti-PAP T cells and proliferative responses were detected in several patients, and there was a suggestion of increased PSA doubling times. This trial clearly demonstrated the feasibility of this approach, setting the stage for future clinical work. Two ongoing trials are underway, the first (NCT01341652) formally evaluates the role of GM-CSF by comparing DNA-PAP vaccination with GM-CSF to GM-CSF alone in men with biochemically recurrent (nonmetastatic) disease. The second trial (NCT00849121) formally evaluates the role of boost vaccinations for this vector, comparing a fixed 12-week boost schedule to variable and more frequent boosting, based on immune response measurements. This second trial is especially interesting in that vaccination schedules are rarely formally optimized in a clinical, treatment setting.
CELL-BASED VACCINES
GVAX Prostate
Description
The development of this vaccine technology was based on the seminal finding that transduction of cancer cells with the cytokine GM-CSF allowed such cells to function as a potent anticancer vaccine in a prevention setting. 38 Generally, allogeneic cell lines have been transduced, and the platform has been clinically evaluated in a number of cancer types, including lung, breast, pancreatic, and prostate cancer. 39 For prostate cancer, 2 cell lines (LNCaP and PC-3) have been used, thus including both an androgen-sensitive and an androgen-resistant cell line to provide broad antigen coverage.
Clinical Development
Clinical evaluation of GVAX prostate proceeded to the stage of 2 randomized phase III trials. The first of these trials (VITAL-1) compared GVAX prostate to standard chemotherapy (docetaxel) for men with mCRPC. In the second trial (VITAL-2), a combination of GVAX prostate and docetaxel was compared with docetaxel alone; this time a more advanced population, men with symptomatic mCRPC, was enrolled. Unfortunately, safety concerns led to the discontinuation of the second trial, with preliminary results suggesting an imbalance in deaths in the combined treatment group. 40 Subsequent follow-up showed those safety concerns to be unfounded, with no statistical difference in mortality between groups. Nevertheless, these concerns prompted an unplanned and slightly underpowered efficacy analysis of the VITAL-1 trial, 41 which indicated futility, leading to the closure of that trial as well. The intellectual property rights to the GVAX platform have been transferred to BioSante, Inc, and current clinical development in prostate cancer involves a planned neoadjuvant study in high-risk men (C. Drake, personal communication, 2011). Ongoing development in other tumor types (melanoma, breast and pancreatic cancer) is robust, with multiple combinatorial trials currently enrolling patients.
CONCLUSIONS
The pivotal Sipuleucel-T trial (D9902B) 4 and the randomized phase II trial of ProstVac VF in a nearly identical patient population 27 provide strong evidence that immunotherapy (''vaccination'') can result in a survival benefit in advanced prostate cancer. This is surprising, as it might have been predicted that vaccines for the so-called immunogenic tumors (melanoma and renal cell cancer) might have been approved earlier. That has not been the case, as a number of trials in those diseases have not been successful in the phase III setting. 42 The precise immunologic mechanisms underlying these differences are not clear but might relate to the might relate to the notion that the prostate gland (at least in the absence of cancer) is immunologically ignored, 12 leading to the potential availability of T cells that have not been centrally deleted to be recruited into the immune response. A second relevant mechanism may involve androgen ablation; most patients with prostate cancer treated with vaccines have been castrate, a physiological state associated with increased immune responsiveness through a number of mechanisms. 13 Future studies will undoubtedly involve earlier application of vaccines, although the relatively long survival of men with prostate cancer makes registration trials in those earlier disease states daunting. Perhaps most exciting is the notion of combining vaccination with monoclonal antibodies blocking immune checkpoints such as CTLA-4, 43 PD-1, 44 or with stimulatory antibodies like anti-41-BB. 45 Indeed, the tripartite combination of standard cancer treatment regimens that minimize tumor burden, immune checkpoint blockade, and finally cancer vaccination may ultimately be required for optimal clinical benefit.
